Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE …

M Yokoi, K Suzuki, T Daimon, M Nakao… - The …, 2017 - nature.com
Resistance to antiemetic treatment with 5-hydroxytryptamine-3 receptor antagonist is an
issue. This study evaluated the potential roles of ABCB1 and ABCG2 polymorphisms in …
被引用次数：23 相关文章

Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE …

D Tsuji, M Yokoi, K Suzuki, T Daimon… - The …, 2017 - go.gale.com
Resistance to antiemetic treatment with 5-hydroxytryptamine-3 receptor antagonist is an
issue. This study evaluated the potential roles of ABCB1 and ABCG2 polymorphisms in …

[引用][C] Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE …

D Tsuji, M Yokoi, K Suzuki, T Daimon… - The …, 2016 - cir.nii.ac.jp
Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with
cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study | CiNii …

Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE …

D Tsuji, M Yokoi, K Suzuki, T Daimon… - The …, 2017 - pubmed.ncbi.nlm.nih.gov
Resistance to antiemetic treatment with 5-hydroxytryptamine-3 receptor antagonist is an
issue. This study evaluated the potential roles of ABCB1 and ABCG2 polymorphisms in …